ImmuPharma PLC (AIM:IMM)'s (LON:IMM) CEO, Tim McCarthy, presents commercial strategy for lupus drug Lupuzor™ as FDA approves PK study in advance to starting the Phase 3 trial, whilst also outlining the new Board’s plans on progressing the Company’s pipeline over the next 12 months.
The study will be carried out in 24 healthy male volunteers, and is expected to take between eight and 12 weeks to complete.
Lupuzor will move into an optimized international Phase 3 trial following the successful completion of the pharmacokinetic study.
McCarthy explains how Lupuzor stacks up against competing drugs in the Lupus space with GSK with Benylsta and now recently approved Astra Zeneca’s Saphnelo.
He also takes viewers through the latest board changes that were announced at the end of July.
as FDA approves PK study in advance to starting the Phase 3 trial, whilst also outlining the new Board’s plans on progressing the Company’s pipeline over the next 12 months”